London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).
AstraZeneca has licensed an experimental rare disease therapy to UK-based Mereo BioPharma, as it continues to shed products outside of its area of strategic focus.
UK-based rare and speciality diseases group Mereo BioPharma says its brittle bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.